JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Pioneering Clinical Investigation: Beta Defensin Expression in Patients of Squamous Cell Carcinoma of Oral Cavity as a Forward-Looking Validation for Molecular Treatment

  • 0Department of Otorhinolaryngology, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan 342005 India.
Indian Journal of Otolaryngology and Head and Neck Surgery : Official Publication of the Association of Otolaryngologists of India +

|

March 12, 2025

|

March 12, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Human Beta Defensin 1 (HBD1) expression increased in head and neck cancers, but Human Beta Defensin 3 (HBD3) showed no expression. Further research is needed to confirm their roles as biomarkers.

Area Of Science

  • Immunology
  • Oncology
  • Molecular Biology

Background

  • Human defensins are immune peptides with varied roles in cancer.
  • Their specific function in head and neck squamous cell carcinoma (HNSCC) remains understudied.
  • Investigating Human Beta Defensin (HBD) 1 and 3 in HNSCC progression is crucial.

Purpose Of The Study

  • To explore the role of HBD1 and HBD3 in HNSCC progression.
  • To assess their potential as diagnostic or prognostic biomarkers for HNSCC.
  • To analyze the gene expression levels of HBD1 and HBD3 in cancerous and normal tissues.

Main Methods

  • Gene expression analysis using mRNA isolation and Polymerase Chain Reaction (PCR).
  • Quantification of HBD1 and HBD3 fold change expression relative to a housekeeping gene (GAPDH).
  • Comparison of expression levels between 26 HNSCC tissue samples and adjacent normal tissues.

Main Results

  • A significant increase (2.85-fold) in HBD1 gene expression was observed in HNSCC tissues compared to normal tissues.
  • No detectable expression of HBD3 was found in either cancerous or normal tissue samples.
  • The ratio of HBD3 to HBD1 expression could not be determined due to the absence of HBD3 expression.

Conclusions

  • HBD1 shows a potential association with HNSCC, warranting further investigation.
  • HBD3 does not appear to be expressed in HNSCC or normal tissues, suggesting it may not be a relevant biomarker.
  • Larger studies analyzing various clinico-histopathological stages are necessary to validate HBD1 as a biomarker.

Keywords: